Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular response
about
Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experienceUsing circulating cell-free DNA to monitor personalized cancer therapy.Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia.Absolute quantification of BCR-ABL1 fusion transcripts in pediatric chronic myeloid leukemia.
P2860
Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular response
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Monitoring of BCR-ABL levels i ...... of a major molecular response
@ast
Monitoring of BCR-ABL levels i ...... of a major molecular response
@en
type
label
Monitoring of BCR-ABL levels i ...... of a major molecular response
@ast
Monitoring of BCR-ABL levels i ...... of a major molecular response
@en
prefLabel
Monitoring of BCR-ABL levels i ...... of a major molecular response
@ast
Monitoring of BCR-ABL levels i ...... of a major molecular response
@en
P2093
P2860
P1476
Monitoring of BCR-ABL levels i ...... of a major molecular response
@en
P2093
Afonso Celso Vigorito
Cármino Antonio de Souza
Irene Lorand-Metze
Israel Bendit
Juarez Pires Tomaz
Katia Borgia Barbosa Pagnano
Marcia Torresan Delamain
Melissa Pereira Machado
Noemi Farah Pereira
P2860
P304
P356
10.5581/1516-8484.20110056
P577
2011-01-01T00:00:00Z